Plasma endothelin-1 level as a predictor for poor collaterals in patients with 95% coronary chronic occlusion

Ying Fan1, Sha Li2, Xiao-Lin Li2

  • 1Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Bei Li Shi Road, Xi Cheng District, Beijing, 100037, China; Department of Cardiology, The Fifth Hospital of Wuhan & Affiliated Guangci Hospital of Wuhan University, Wuhan 430050, China.

Thrombosis Research
|April 23, 2016
PubMed

Insights

Higher endothelin-1 (ET-1) levels predict poor coronary collateral circulation (CCC) in patients with severe coronary artery occlusion. This finding suggests ET-1 is a valuable marker for assessing CCC, aiding in myocardial protection strategies.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Biomarker Research

Background:

  • Coronary collateral circulation (CCC) is crucial for myocardial protection during ischemia.
  • Identifying predictors of CCC is clinically significant for managing ischemic heart disease.
  • Endothelin-1 (ET-1) is investigated as a potential factor influencing CCC.

Purpose of the Study:

  • To evaluate endothelin-1 (ET-1) as a predictor of coronary collateral circulation (CCC) quality.
  • To assess ET-1 levels in patients with significant coronary artery occlusion (≥95%).

Main Methods:

  • Screened 1038 patients with ≥95% coronary artery occlusion.
  • Classified patients into poor (Rentrop 0-2) and good (Rentrop 3) CCC groups.
  • Assessed the association between plasma ET-1 levels and collateral status.

Main Results:

  • Patients with poor CCC had significantly higher ET-1 levels than those with good CCC (0.59±0.48 vs. 0.39±0.32 pmol/L, p<0.001).
  • ET-1 levels showed a significant trend of increase with decreasing Rentrop grades (p<0.001).
  • Multivariate analysis confirmed ET-1 as an independent predictor of poor CCC (OR 2.27 [1.60-3.22], p<0.001), significant in both sexes.

Conclusions:

  • Plasma ET-1 levels are a useful and accessible marker for predicting the degree of CCC.
  • Elevated ET-1 is associated with poorer collateralization in severe coronary occlusions.
  • ET-1 may aid in risk stratification and management of patients with ischemic heart disease.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
730
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
937
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
537